Morningstar Investment Management LLC Buys Shares of 5,482 Hologic, Inc. $HOLX

Key Points

• Morningstar Investment Management LLC acquired 5,482 shares of Hologic, Inc., valued at approximately $357,000, during the 2nd quarter.
• Hologic's quarterly earnings surpassed expectations, reporting $1.08 EPS against an analyst consensus of $1.05, with revenue at $1.02 billion.
• Several analysts have given Hologic a consensus rating of "Moderate Buy" with a price target averaging $80.15, while 94.73% of the company’s stock is owned by institutional investors.

Morningstar Investment Management LLC bought a new stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 5,482 shares of the medical equipment provider's stock, valued at approximately $357,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Greenleaf Trust grew its stake in shares of Hologic by 5.1% in the 2nd quarter. Greenleaf Trust now owns 3,579 shares of the medical equipment provider's stock valued at $233,000 after buying an additional 173 shares in the last quarter. Beverly Hills Private Wealth LLC grew its stake in shares of Hologic by 3.6% in the 1st quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider's stock valued at $320,000 after buying an additional 180 shares in the last quarter. Allworth Financial LP grew its stake in shares of Hologic by 46.0% in the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock valued at $40,000 after buying an additional 216 shares in the last quarter. First American Bank grew its stake in shares of Hologic by 0.9% in the 2nd quarter. First American Bank now owns 28,705 shares of the medical equipment provider's stock valued at $1,870,000 after buying an additional 245 shares in the last quarter. Finally, SPC Financial Inc. grew its stake in shares of Hologic by 2.2% in the 2nd quarter. SPC Financial Inc. now owns 12,859 shares of the medical equipment provider's stock valued at $838,000 after buying an additional 278 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

Hologic Stock Up 0.6%

Shares of HOLX stock opened at $65.92 on Wednesday. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.39. The firm has a market cap of $14.66 billion, a PE ratio of 27.35, a price-to-earnings-growth ratio of 2.25 and a beta of 0.63. The stock has a 50 day moving average of $67.06 and a 200-day moving average of $63.38. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same period in the previous year, the company earned $1.06 earnings per share. The company's quarterly revenue was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Weiss Ratings reissued a "hold (c-)" rating on shares of Hologic in a research note on Wednesday, October 8th. Stephens reaffirmed an "overweight" rating and set a $78.00 target price on shares of Hologic in a research report on Thursday, September 18th. Mizuho set a $75.00 target price on Hologic in a research report on Thursday, July 31st. UBS Group upped their target price on Hologic from $65.00 to $70.00 and gave the stock a "neutral" rating in a research report on Thursday, July 31st. Finally, Citigroup raised Hologic from a "neutral" rating to a "buy" rating and upped their target price for the stock from $60.00 to $80.00 in a research report on Wednesday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $80.15.

Insider Activity at Hologic

In other news, CEO Stephen P. Macmillan sold 138,358 shares of the company's stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the transaction, the chief executive officer directly owned 1,234,624 shares in the company, valued at $82,682,769.28. The trade was a 10.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.88% of the stock is currently owned by company insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.